Your browser doesn't support javascript.
loading
PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.
Avilés-Salas, Alejandro; Cabrera-Miranda, Luis; Hernández-Pedro, Norma; Vargas-Lías, Diana Sofía; Samtani, Suraj; Muñoz-Montaño, Wendy; Motola-Kuba, Daniel; Corrales-Rodríguez, Luis; Martín, Claudio; Cardona, Andrés F; Palomares-Palomares, Cittim B; Arrieta, Oscar.
Afiliación
  • Avilés-Salas A; Pathology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Cabrera-Miranda L; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Hernández-Pedro N; Personalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Vargas-Lías DS; Pathology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Samtani S; Medical Oncology Department, Clínica Las Condes Santiago, Santiago, Chile.
  • Muñoz-Montaño W; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Motola-Kuba D; Departments of Biomedical Research and Gastroenterology and Liver Unit and Hemodialysis Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
  • Corrales-Rodríguez L; Medical Oncology Department, San Juan de Dios Hospital, San José, Costa Rica.
  • Martín C; Department of Medicine, Western University, London, ON, Canada.
  • Cardona AF; Thoracic Oncology Unit and Direction of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
  • Palomares-Palomares CB; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.
  • Arrieta O; Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia.
Front Oncol ; 13: 1269029, 2023.
Article en En | MEDLINE | ID: mdl-38111532
ABSTRACT

Background:

Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used to predict the benefit of chemotherapy treatment. This study aimed to determine the prognostic value of PD-L1 expression and its addition to CALGB scoring system in patients with MPM.

Methods:

In this retrospective analysis, we evaluated samples with confirmed locally advanced or metastatic MPM. PD-L1 Tumor Proportional Score (TPS) was determined by immunohistochemistry at diagnosis.

Results:

73 patients were included in this study. A cutoff value of 15 was set for a high or low PD-L1 TPS. In total, 71.2% (n=52) and 28.8% (n=21) of individuals harbored low or high PD-L1 expression, respectively. PD-L1High was associated with worse median progression-free Survival (mPFS) [4.9 vs. 10.8 months; HR 2.724, 95% CI (1.44-5.14); p = 0.002] and Overall Survival (OS) [6.0 vs. 20.9 months; HR 6.87, 95% CI (3.4-8.7); p<0.001] compared to patients with PD-L1Low. Multivariate analysis confirmed that PD-L1 expression was an independent factor for PFS and OS in patients with MPM and CALGB score of 5-6.

Conclusion:

PD-L1 addition to CALGB scale improves its prognostic estimation of MPM survival and should be considered in future research.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza